Synchrony in social groups may confer significant evolutionary advantages by improving group cohesion and social interaction. However, the neurobiological mechanisms translating social synchrony into refined social information transmission between interacting individuals are still elusive. In two successively conducted experiments involving a total of 306 healthy volunteers, we explored the involvement of the neuropeptide oxytocin (OXT) in reciprocal social interaction. First, we show that synchronous social interactions evoke heightened endogenous OXT release in dyadic partners. In a second step, we examined the consequences of elevated OXT concentrations on emotion transmission by intranasally administering synthetic OXT before recording emotional expressions. Intriguingly, our data demonstrate that the subjects’ facial and vocal expressiveness of fear and happiness is enhanced after OXT compared with placebo administration. Collectively, our findings point to a central role of social synchrony in facilitating reciprocal communication between individuals via heightened OXT signaling. Elevated OXT concentrations among synchronized individuals seem to augment the partners’ emotional expressiveness, thereby contributing to improved transmission of emotional information in social communication.

Humans are an unusually prosocial species, who engage in social behaviors that include altruism—whereby an individual engages in costly or risky acts to improve the welfare of another person—care, and cooperation. Current perspectives on the neurobiology of human prosociality suggest that it is deeply rooted in the neuroendocrine architecture of the social brain and emphasize the modulatory role of the neuropeptide hormone oxytocin. In this review, we provide a conceptual overview of the neurobiology of prosocial behavior with a focus on oxytocin’s modulatory role in human prosociality. Specifically, we aim to encourage a better understanding of the peptide’s susceptibility to diverse factors that produce heterogeneity in outcomes and the resulting methodological implications for measuring the behavioral effects of oxytocin in humans. After providing an overview of the state-of-the-art research on oxytocin’s exogenous use, we elaborate on the peptide’s modulatory role in the context of care-based altruism, cooperation, and conflict and discuss its potential for therapeutic interventions in psychiatric disorders characterized by social dysfunction.

Current psychological concepts of social and ecological responsibility emphasize the relevance of altruism, suggesting that more altruistic individuals are more likely to engage in sustainable behaviors. Emerging evidence indicates a central role of the neuropeptide oxytocin in promoting altruism. Whether this influence extends to ecological responsibility or is limited to the social domain remains unknown. In two independent experiments involving 172 human participants, we addressed this question by exposing subjects to a sustainability-related monetary donation task, with the option to support either socially or ecologically framed charities. We found that oxytocin induced a context-dependent change in altruistic behavior away from pro-environmental toward pro-social donations, while keeping constant the overall proportion of donated money. This pro-social bias transcended to the domain of sustainable consumption. Collectively, our findings demonstrate that altruistic priorities vary as a function of oxytocin system activity, which has implications for the promotion of pro-environmental attitudes and eco-friendly behaviors.

Benzodiazepines (BZDs) represent the gold standard of anxiolytic pharmacotherapy; however, their clinical benefit is limited by side effects and addictive potential. Consequently, there is an urgent need to develop novel and safe anxiolytics. The peptide hormone oxytocin (OXT) exhibits anxiolytic-like properties in animals and humans, but whether OXT and BZDs share similar effects on the neural circuitry of fear is unclear. Therefore, the rationale of this ultra-high-field functional MRI (fMRI) study was to test OXT against the clinical comparator lorazepam (LZP) with regard to their neuromodulatory effects on local and network responses to fear-related stimuli. One hundred twenty-eight healthy male participants volunteered in this randomized double-blind, placebo-controlled, between-group study. Before scanning using an emotional face-matching paradigm, participants were randomly administered a single dose of OXT (24 IU), LZP (1 mg), or placebo. On the behavioral level, LZP, but not OXT, caused mild sedation, as evidenced by a 19% increase in reaction times. On the neural level, both OXT and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA). In contrast, they had different effects on intra-amygdalar connectivity; OXT strengthened the coupling between the cmA and basolateral amygdala, whereas LZP increased the interplay between the cmA and superficial amygdala. Furthermore, OXT, but not LZP, enhanced the coupling between the cmA and the precuneus and dorsomedial prefrontal cortex. These data implicate inhibition of the cmA as a common denominator of anxiolytic action, with only OXT inducing large-scale connectivity changes of potential therapeutic relevance.

McLeod phenotype red cells of the Kell blood group system have acanthocytic morphology and reduced in vivo survival. The phenotype has an X-linked mode of inheritance and is found in some males who have no abnormality of leukocyte function and in some who have X-linked chronic granulomatous disease (CGD). We now describe an association between the McLeod phenotype and an abnormal elevation of serum creatine phosphokinase (CPK). The increase is of the MM isoenzyme type, derived from skeletal muscle or cardiac muscle, and muscle biopsy shows evidence of muscle cell changes. All of 11 males who have McLeod syndrome but do not have CGD have high levels of serum CPK. Males with McLeod syndrome and CGD may have normal or high levels of the enzyme. Individuals with other variant phenotypes in the Kell system have normal levels of serum CPK. Studies on a large kindred, which includes 5 people of McLeod phenotype, show high CPK levels only in the members of McLeod type. We conclude that the high level of CPK in the serum of these people is a reflection of a muscle cell anomaly and that in these individuals it is a pleiotropic effect of the X-linked gene that produces the McLeod red cell phenotype.